Compared with peripheral delivery, portal glucose delivery is more effective at stimulating hepatic glucose uptake and glucose incorporation into glycogen, an effect attributed to the "portal glucose" signal (12) . Concomitantly, the portal glucose signal brings about a suppression of nonhepatic (primarily skeletal muscle) glucose uptake (25) . During the last 10 years, studies using the pancreatic clamp technique have extended the portal signaling concept to AAs (16, 45) , and studies have begun to define the interaction between glucose and AA metabolism in the liver (37, 38) . In the presence of hyperglycemia generated by peripheral glucose delivery, the peripheral venous infusion of AA, so as to elevate the hepatic AA load twofold, had no impact on liver protein synthesis compared with a control group in which the AA load to the liver was maintained basal. However, when the AA were infused into the portal vein, but again with the hepatic AA load doubled, liver protein synthesis was increased in association with stimulation of an mammalian target of rapamycin (mTOR)-dependent signaling pathway (16) . Thus, the delivery of glucose or AA into the portal vein appears to initiate a potent signal to induce the storage of those nutrients in the liver during the postprandial period.
There is also evidence that the portal glucose and AA signals interact. Moore and colleagues (37, 38) conducted a series of experiments with concomitant infusion of gluconeogenic AA and glucose either peripherally or portally (37, 38) . They concluded that portal but not peripheral infusion of glucose limited net hepatic AA uptake (serine and glutamine), which may lead to a reduction of hepatic protein synthesis because some amino acids may become limiting. The uptake of AA by the different tissues is under the control of a variety of AA transporters. Most cells express the transport systems known as A, ASC, and L, and each has specific AAs that are preferably transferred (35) . It is not clear whether portal vein delivery of nutrients impacts the activity of these different transporters. Nevertheless, the way in which the portal glucose and AA signals interact to regulate postprandial nutrient disposition needs to be elucidated, and the role of the portal glucose signal on both liver and nonhepatic protein synthesis remains unknown.
In this context, the purpose of the present study was to compare protein synthesis rates in the liver and muscle in response to portal or peripheral glucose infusion with simultaneous intraportal infusion of a complete AA mixture in the conscious dog. Our hypothesis was that the portal glucose signal would interact with the portal AA signal and blunt the hepatic protein synthetic rate. Furthermore, we anticipated that the portal glucose signal would decrease glucose uptake in nonhepatic tissues (muscle), and that would also lead to an increase in AA utilization by muscle for energy.
MATERIALS AND METHODS

Animals and Surgical Procedures
Studies were performed on 42-h-fasted, conscious, adult male mongrel dogs (20 -25 kg; n ϭ 15). Housing and diets have been described previously (16) . The protocol was approved by the Vanderbilt University Medical Center Animal Care Committee and followed the American Association for the Accreditation of Laboratory Animal Care International guidelines. About 16 days before the study, each dog underwent a laparotomy under general anesthesia to place silastic catheters (Dow Corning, Midland, MI) into the portal vein, a hepatic vein, and a femoral artery for blood sampling and into a jejunal vein and a splenic vein for infusion (described previously in Refs. 2 and 36). Ultrasonic flow probes (Transonic Systems, Ithaca, NY) were placed around the portal vein and hepatic artery. On the day of the experiment, the catheters were exteriorized under local anesthesia (2% lidocaine; Hospira, Lake Forest, IL), and intravenous access was established in three additional peripheral veins. The dog was then placed in a Pavlov harness.
Experimental Design
In each group, the protocol consisted of an equilibration period (0 -90 min) and a basal period (90 -120 min) followed by an experimental period (120 -300 min). At 0 min, a primed (40 Ci), continuous (0. ; Eli Lilly, Indianapolis, IN) infusions were started through the splenic and jejunal catheters. AA infusion was also started via the portal vein at 120 min (0.034 ml·kg Ϫ1 ·min Ϫ1 ). The composition of the AA mixture (Table 1) was determined in a previous study (16 . Femoral artery, portal vein, and hepatic vein blood samples were taken, and blood flow was monitored as described elsewhere (2) . At the end of the 300-min study, animals were euthanized and samples of each liver lobe and the sartorius muscle (mixed type muscle in the hindlimb) rapidly freeze-clamped and stored at Ϫ80°C.
Analytical Procedures
Plasma glucose, insulin, and glucagon concentrations were measured as described previously (40) . Plasma AAs were analyzed by ion exchange HPLC with lithium citrate buffer system and post-column ninhydrin quantification (Biochrom US, Holliston, MA). Free and bound leucine-specific radioactivities were determined as described by Donahue et al. (20) . Plasma albumin was isolated by ethanol extraction from trichloroacetic acid-precipitated plasma proteins, as described previously (34) . Plasma IGF-I was analyzed by ELISA (ALPCO Diagnostics, Salem, NH).
Calculations
Hepatic load (mol·kg Ϫ1 ·min Ϫ1 ). The load of a substrate or hormone reaching the liver (load in) was calculated as
where Fa and Fp are the arterial and portal flows (ml·kg Ϫ1 ·min Ϫ1 ), respectively, and Ca and Cp are the concentrations of the variables in question in arterial and portal blood or plasma, respectively, as appropriate.
Estimated hepatic sinusoidal plasma hormone concentrations were calculated as load in/total hepatic plasma flow.
The load of substrate exiting the liver (load out) was calculated as
where Fh is the hepatic vein flow (ml·kg Ϫ1 ·min Ϫ1 ) or the sum of Fa and Fp, and Ch is the concentration of the variable in question in the hepatic vein blood or plasma, as appropriate.
Net hepatic substrate balance (mol·kg Ϫ1 ·min Ϫ1 ). Whole blood glucose concentrations and plasma AA concentrations were used, along with blood or plasma flow, as appropriate, to assess net hepatic substrate balance (NHSB). NHSB was calculated as NHSB ϭ load out Ϫ load in.
A positive value represents net production, and a negative value represents net uptake of the substrate by the liver.
Hepatic fractional extraction (%). The fractional extraction by the liver corresponded to the NHSB divided by the load reaching the liver for that substrate:
Net portal drained viscera uptake. The balance of nutrients across the portal drained viscera [PDV; of which the gut represents the largest portion and is thus termed "net gut balance" in our previous publications (e.g., see Ref. 36 )] was calculated just as for net hepatic balance, except that nutrients infused into the portal vein were subtracted: ) and Leu plasma Sa is the specific activity of leucine in the plasma under steady state (cpm/mol).
As described elsewhere (11) at equilibrium,
where S is the rate of leucine incorporation into protein, C is the rate of leucine oxidation, P is the rate of leucine release from protein (an estimate of whole body protein breakdown), and I is the rate of exogenous leucine input (infusion or intake). In our case, oxidation was not measured and prevented the calculation of protein synthesis, but we had access to the amount of leucine infused. Thus it was possible to calculate the whole body protein proteolysis as
Western Blot Analysis
Liver and muscle samples were prepared for extraction of total protein under conditions that inhibit endogenous protease, kinase, and phosphatase activities. Normalization of samples, electrophoretic separation blotting, and immunodetection of proteins were performed as described previously (22) . Antibodies specific for total and phosphorylated AMP-activated protein kinase (AMPK), Akt, mTOR, 4E-BP1, and p70S6K (respectively phosphorylated on Thr 172 , Ser 473 , Ser 2448 , Thr 70 , and Thr 389 ) were purchased from Cell Signaling Technology. Antibody incubation, washing, and exposure conditions were optimized for each antibody individually, as was done previously (22) . Actin was used as a loading control for all test proteins. Blots probed with phosphospecific antibodies were stripped and reprobed with antibodies against the respective total protein. Thus, data for phosphoproteins were corrected for the respective total protein. Test protein bands in the linear signal range were quantified using Image J software (http://rsb.info.nih.gov/ij/).
RNA Extraction, cDNA Synthesis, and Real-Time PCR
Total RNA was extracted by homogenizing 50 mg of liver or muscle in 1 ml of Tri Reagent (Sigma, St. Louis, MO), following the manufacturer's instructions. The RNA pellet was dissolved in nuclease-free Tris-EDTA buffer. The purity of the RNA in solution was verified on the basis of A260/A280 ratios Ͼ1.8. cDNA was synthesized from RNA using the High Capacity reverse transcription kit (Applied Biosystems, Foster City, CA). Primer pairs were designed and analyzed specifically for canine material using Premier Biosoft International Beacon Designer Software (Palo Alto, CA). The sequences of canine primer pairs for AA transport systems A, L, and system amino acid soluble carrier (ASC) AA transporter (ASCT) were as follows: SLC38-A2, 5=-TGGCTAATACTG-GAATTG-3= and 5=-AAGGAGATGAACAGAATAC-3=; SLC7-A5, 5=-CTTCTCCGTCATCAACTT-3= and 5=-GCCAGGATGAAGAATACT-3=; SLC1-A5, 5=-CTCATCCGCTTCTTCAAC-3= and 5=-ATCCTC-CATCTCCACAAT-3=; CASP3, 5=-TTATCCTGAAATGGGTTTA-3= and 5=-AAGTTTGTGAATGTTTCC-3=; CAPN2, 5=-GTCGTAACCA-GACATCCT-3= and 5=-GTTGTTCCACAGATACTTGA-3=; and for the housekeeping gene RPL13, 5=-GCCGGAAGGTTGTAGTCGT-3= and 5=-GGAGGAAGGCCAGGTAATTC-3=. Real-time PCR analysis was performed using iQ SYBR Green Supermix fluorophore (Bio-Rad) and the following protocol: step 1, 95°C for 3 min (1 time); step 2, 95°C for 10 s; and step 3, 55°C for 30 s (steps 2 and 3 were repeated 39 times). Target genes were normalized to RPL13 (reference gene) using the Livak and Schmittgen (32) method and expressed relative to the PeG group of animals.
Statistical Analysis
Data are expressed as means Ϯ SE and were analyzed using Sigma Plot 11 (Systat Software, San Jose, CA). For glucose and hormones, time course data were analyzed by two-way analysis of variance for repeated measures to identify any effect of the route of delivery of glucose, time, and the interaction between the route of delivery and time. Differences were considered significant when P Ͻ 0.05, and a tendency was considered for 0.05 Ͻ P Ͻ 0.10. For AA, values were calculated as the mean of individual values recorded between 210 and 300 min and for protein synthesis and signaling; the final value is a mean of the values obtained for two separate analyses on two separate lobes of the liver or two separate pieces of sartorius muscle. Statistical evaluations of these data were performed by two-tailed Student t-test to analyze the effect of the route of delivery of glucose with the same significance and tendency as described earlier.
RESULTS
Hormone Levels, Hepatic Blood Flow, and Glucose Metabolism
Arterial and hepatic sinusoidal insulin and glucagon concentrations increased as expected (Fig. 1 ) and were similar in both groups during the basal and the experimental periods. Arterial plasma IGF-I concentrations during the final hour of study did not differ between groups (273 Ϯ 24 and 267 Ϯ 78 ng/ml in PeG and PoG, respectively). There were no differences in hepatic artery or portal vein plasma flow between the two groups ( Table 2) . Arterial plasma glucose levels increased in the two groups from 108 Ϯ 2 to 160 Ϯ 1 and 159 Ϯ 4 mg/dl for PeG and PoG, respectively ( Fig. 2A) . During the experimental period, the hepatic glucose loads increased proportionally (by 30 and 36% compared with basal values for PeG and PoG, respectively) and did not differ significantly between the two groups (data not shown). During the experimental period, the arterioportal (A-P) glucose gradient in the PoG group was negative and significantly different from that in the PeG group (Fig. 2B ). The two groups exhibited similar rates of net hepatic glucose output during the basal period (1.3 Ϯ 0.1 and 1.2 Ϯ 0.1 mg·kg Ϫ1 ·min Ϫ1 for PeG and PoG, respectively). With the start of the experimental period, both groups switched to net uptake of glucose (Fig. 2C ), but nonhepatic glucose uptake was greater in the PoG group. Conversely, nonhepatic uptake of glucose was lower in the PoG group (Fig. 2D ).
AA and Protein Metabolism
The A-P gradients and the hepatic loads for total and individual AA were not significantly different between the groups (with the exception of the hepatic load of Glu), implying that the clamp was successful ( Table 3 ). The hepatic fractional extractions of total and individual AA were also similar for the two groups during both the basal period (data not shown) and the experimental period (Table 3) . During the experimental period, arterial concentrations of Asp, Cys, Met, His, Trp, and Pro did not differ between the two groups. The arterial glutamate concentration tended to be higher (by 30%) for the group with portal glucose infusion, but the arterial concentrations for the other 13 AAs, as well as the sum of the 20 AAs, were significantly lower in the group with portal glucose infusion. Note that the goal was to fix the hepatic loads and portal concentrations of the individual AA, not to equalize the arterial AA concentrations. The site of glucose infusion did not affect the net PDV uptake of individual and total AAs (Table 3) .
Arterial plasma leucine-specific radioactivity was constant and similar between the two groups throughout the last 3 h of the experimental period (Fig. 3) , confirming that a steady state of leucine Sa was achieved. Table 4 also shows that both portal and hepatic vein-specific activities were similar for both groups and that the precursor pool in the liver and the muscle was not affected by portal infusion of glucose. As calculated from arterial plasma leucine-specific activity, Table 4 also shows that whole body proteolysis was not modified between the two groups. Liver protein synthesis was measured in the largest lobes [the left central and left lateral, totaling 39% of total liver weight (1)] at the end of the experiment. Portal delivery of glucose did not modify synthesis of constitutive liver protein (Fig. 4A) or albumin (data not shown). Consistent with this, there was no difference in the phosphorylation states of AMPK, Akt, or proteins in the mTOR signaling pathway (Fig. 4B) .
In contrast, the portal glucose signal was associated with increased skeletal muscle protein synthesis such that the incorporation of leucine into muscle protein was 25% greater (Fig.  4C) in the PoG group. In accord with this, during the portal infusion of glucose, p70S6K (Ser 389 ) phosphorylation was increased significantly in muscle (Fig. 4D) . The phosphorylation of AMPK, Akt, mTOR, and eukaryotic initiation factor 4E-binding protein-1 (4E-BP1) in muscle was not modified by portal glucose infusion, and neither was proteolytic enzyme expression (caspase 3 and m-calpain; Fig. 4E ). Likewise, muscle expression of the AA transporter gene SLC38-A2 [or system A transport of AA (SNAT2)] was not altered by the portal glucose signal, but the muscle expression of SLC7-A5 [or system L AA transporter 1 (LAT1) and SLC1-A5 (or ASCT2)] was increased by 47 and 52%, respectively, and was correlated with the increase observed for protein synthesis (Fig. 4E) .
DISCUSSION
Hepatic Metabolism
Previously, we determined that the portal venous delivery of a balanced mixture of AAs, but not peripheral venous AA delivery, stimulated liver protein synthesis in the presence of hyperinsulinemia, hyperglucagonemia, and hyperglycemia created by peripheral glucose infusion (16) . Our current data expand on the previous findings by demonstrating that the route of glucose delivery also impacts the protein synthetic response. When glucose was delivered into the portal vein, with a concomitant portal venous infusion of the AA mixture, the synthesis of constitutive liver proteins and albumin was not significantly different from that evident with peripheral venous delivery of glucose [however, based on our previous data, both groups would have had enhanced hepatic protein synthesis compared with animals with basal AA concentrations (16)]. Nevertheless, concomitant portal glucose and AA delivery did result in an increase in skeletal muscle protein synthesis. Consistent with these findings, in the liver there were no differences between groups in phosphorylation of the molecular markers in the protein synthetic pathway examined, but there was an increase in phosphorylation of p70S6K, a protein downstream of mTOR, in the muscle in PoG. The main focus of this study was the liver, since it is a primary regulator of the nutrient supply to the other tissues and organs, because ingested carbohydrates and AAs go to the liver via the portal vein before entering the systemic circulation. In the presence of the portal glucose signal, net hepatic glucose uptake in the current studies was greater than during peripheral glucose delivery, as demonstrated in previous studies (15, 25, 39, 47) . In the current case (portal vein AA infusion), the hepatic fractional extraction of glucose was augmented fourfold by the portal glucose signal. In a previous study in which only gluconeogenic AAs (as opposed to all AAs) were infused intraportally along with glucose, the portal glucose signal seemed to be blunted (38) . The portal glucose signal has been associated with a translocation of glucokinase from the nucleus to the cytoplasm in the liver of rats and mice, where it exerts its activity and induces increased glucose uptake and glycogen synthesis (14, 15) . Under postprandial conditions, one of the major fates of gluconeogenic AAs in the liver is glycogen synthesis (6) . The current data suggest that AA incorporation into hepatic glycogen was not modified by the portal glucose signal when AAs were delivered concurrently via the portal vein. Indeed, the net hepatic fractional extractions of AAs were similar in the PeG and PoG groups. AA sensors are present in the hepatoportal region (45, 46) , and so are glucose sensors (10, 44), but little is known about interaction between them. Our initial hypothesis was that the portal glucose signal would interfere with the portal AA signal, and a competition between the nutrients would occur. Thus we anticipated that the portal glucose signal might blunt the stimulation of hepatic protein synthesis observed with the portal AA signal alone (16) . Our hypothesis proved to be incorrect, and the AA and glucose portal signals seem to be able to coexist with both substrates controlling their own fate in the liver.
Nonhepatic Metabolism
Despite the lack of difference in the liver fractional extraction or fate of AAs based on the route of glucose delivery, the finding of lower circulating concentrations of most AAs during PoG implied that AA extraction by other tissues increased. This encouraged us to look closer at the nonhepatic metabolism of AAs and glucose. The portal glucose signal redistributes glucose disposition by different organs by promoting net hepatic glucose uptake and glycogen storage while blunting muscle glucose uptake (thus avoiding hypoglycemia) (25, 39) . Under the study conditions, nonhepatic glucose uptake is primarily a reflection of skeletal muscle uptake of glucose (25) , and this was clearly stimulated in the PeG vs. PoG group.
It is important to note that the AAs (and glucose in the PoG group) were actually infused into jejunal and splenic veins that merge into the portal vein. That double infusion was done to promote mixing and avoid streaming of the infusate through the portal vein into the hepatic vein. The assessment of substrate concentrations during portal substrate infusion is complicated by the laminar flow in the portal vein (50) , which can result in inadequate mixing of infusates with the portal blood. Hepatic balance can be calculated with an indirect method that reduces the likelihood of error, but the PDV balance cannot. Thus the PDV balance data cannot be taken as definitive. Nevertheless, there was no evidence that portal glucose delivery affected net uptake of AAs by the PDV. In young pigs, chronic enteral nutrition increased the fractional protein syn- thesis rate in the small bowel (21) and prevented intestinal atrophy, but our focus was on the acute effect of a meal and not long-term effects of parenteral and enteral nutrition. Moreover, our glucose and AA infusions were delivered directly into the portal circulation and thus were downstream of the PDV, not allowing the first-pass uptake of AAs or other nutrients by the small intestine, as would actually occur during a meal. Our model mimics the postprandial conditions at the liver in that there is an increase in hormones and nutrients in the presence of the portal glucose and AA signals. Thus, accepting the PDV balance data at face value, the higher nonhepatic fractional extraction of AA in the PoG group is not attributable to the gut but to nonsplanchnic tissues, consistent with the greater AA incorporation into muscle proteins. Several studies have examined the effect of glucose on protein metabolism in animal models (30, 31, 51) or in vitro (48, 51, 56) , and overall the stimulatory effect of glucose on muscle protein synthesis seems to be clear. However, our study is unique since it incorporates the control of hormone concentrations, the physiological route of glucose delivery, and the ability to assess interactions between the liver and skeletal muscle tissues while separating the liver from the remainder of the PDV. The glucose effect on protein metabolism seems not to be mediated via a direct effect on mTOR phosphorylation but instead may exert a permissive effect for other well-known regulatory factors such as insulin or leucine, as described previously (48) . Our study also documents that the glucose effect on protein synthesis can be different in the liver and in the muscle and can be influenced by the route of glucose supply.
Signaling Pathways in the Liver
Under these experimental conditions and after 3 h of portal venous infusion of glucose and AAs, neither AMPK, Akt, nor mTOR phosphorylation in the liver was different between our groups. Portal glucose delivery stimulates net hepatic uptake of glucose, and one could speculate that the AMP/ATP level would decrease, and in turn AMPK phosphorylation would decrease. However, with high concentrations of glucose and AAs provided to the liver for 3 h, we believe that AMPK was already at a low level of phosphorylation, and that is why we do not see any difference in AMPK signaling. Indeed, values for AMPK phosphorylation in 42-h-fasted dogs are five to six times higher than in the current dogs (data not shown). AMPK phosphorylation was not influenced by feeding in neonatal pigs in numerous organs, including liver, muscle, and pancreas (27) . This is in general agreement with our data in that AMPK did not appear to be necessary for regulation of protein synthesis when glucose and AA supplies were adequate to support the process.
Signaling Pathways in the Muscle
At the muscle level, the PoG group exhibited a higher protein synthetic rate, and muscle p70S6K phosphorylation was increased compared with the PeG group. This kinase, downstream of mTOR, acts on ribosomal protein S6, subsequently initiating protein synthesis (29) . In our case, mTOR and p70S6 responses were not synchronized as expected. Jeyapalan et al. (30) showed that in young pigs muscle but not liver protein synthesis was increased during a hyperglycemic clamp, and neither AMPK nor mTOR phosphorylation was involved in this enhancement. Additionally, in alloxan diabetic rats untreated with insulin, the stimulation of protein synthesis by leucine was not accompanied by phosphorylation of either 4E-BP1 or p70S6K (5) . The fact that mTOR phosphorylation and its downstream elements 4E-BP1 and p70S6K are not correlated can be attributed to the fact that p70S6 phosphorylation is less transient and is more representative of changes over a long experimental protocol (16) . Two hours after a single meal, mTOR, S6K1, and 4E-BP1 phosphorylation were all reduced to fasting values compared with a peak activation just 30 min after the meal (27) . Thus, the time course of our experiment and the timing of tissue collection could explain the lack of effect on signaling protein phosphorylation, i.e., phosphorylation is transient and responds to changes in nutrient supply and hormone concentrations. It is possible that there Data are means Ϯ SE; n ϭ 6/group. A-P, arterioportal; PDV, portal drained viscera; TAA, total AA; NEAA, nonessential AA; EAA, essential AA; BCAA, branched-chain AA. The statistical evaluation of the data was performed by a t-test. **Differences were considered significant when P Ͻ 0.05. *There was a tendency for 0.05 Ͻ P Ͻ 0.10. was an effect of the glucose portal signal on IGFBP-3 concentrations that contributed to the difference in muscle protein synthesis (53) , but in the absence of differences in IGF-I concentrations and Akt phosphorylation between groups, this seems unlikely.
Proteolytic enzyme gene expression was measured in the muscle, and no differences between the two groups were found for caspase-3 or m-calpain (Fig. 4) . This lack of change in molecular markers of proteolysis is in agreement with the findings of a recent investigation of the effect of nutritional factors (high-protein diet) on hepatic and muscle protein metabolism (13). Thus, there was no evidence for stimulation of proteolysis concomitant with the stimulation of muscle protein synthesis.
AA Transporters
Nutrition is known to regulate the expression of genes responsible for AA transport in the liver and in the muscle (23, 24, 54) , and a number of transporters have been described, with high selectivity in AAs transported (33) . Moreover, LAT1 and ASCT2 [system L and system ASC transporters, which are in Sa, specific activity. Data for plasma values are the average of the last 2 h Ϯ SE; the statistical evaluation of the data was performed by an ANOVA with the route of glucose infusion and the time as factors, and the P value is the one for the route of glucose infusion. Data for tissue values are means of 2 separate measurements for each dog Ϯ SE; the statistical evaluation of the data was performed by a t-test. Differences were considered significant when P Ͻ 0.05. Whole body proteolysis is calculated as the flux of leucine (arterial Sa leucine/Sa leucine in the infusate) minus the leucine infused. charge of large hydrophobic neutral or small anionic AAs, respectively (8) ] are involved in the regulation of mTOR by increasing AA availability, notably leucine (42, 43) . In our study, where the hepatic load of AA was clamped and similar in the two groups, we observed a lower arterial plasma concentration of AA in the PoG group. We hypothesized that portal glucose delivery induced a stimulation of a transporter of AA at the muscle level that could explain a higher availability of substrate for protein synthesis in that tissue. In the PoG group, LAT1 and ASCT2 expression (SLC7A5 and SLC1A5, respectively) were increased. We also measured SNAT2 because it is regulated by factors such as nutrition and insulin elsewhere (52) , but that system, identified to typically transport small and polar neutral AAs (8), showed no difference in the expression of its gene (SLC38A2).
Conclusions
From a clinical standpoint, it has been well documented that AA delivery, particularly that of leucine, improves muscle protein synthesis in the elderly (49) , in trauma patients with sepsis (9) , and in recovery after exercise (4) . Glucose delivery via peripheral vein has been shown to enhance protein synthesis in the muscle but not in the liver (30) in neonatal pigs. The effects of the peripheral and portal/enteral glucose delivery routes on protein synthesis have not previously been compared. Our data indicate that entry of glucose via the portal route has an advantage over the peripheral route in the stimulation of muscle protein synthesis, whereas the splanchnic AA metabolism did not appear to change. That is potentially very important for increasing and/or maintaining muscle mass in the elderly (55) , for postexercise recovery (28), or during enteral or parenteral nutrition support (18) .
Under postprandial conditions, the coordination of tissue responses is essential for the channeling of nutrients toward areas of storage and synthesis. Our results show that the portal glucose signal is an important factor for that channeling, since it has effects in both the liver and the muscle, not only on glucose metabolism but also on AA metabolism and more particularly on AA utilization for protein synthesis. Several lines of evidence indicate that the portal glucose signal is neurally mediated (1, 19) . However, additional investigations will be needed to determine the exact mechanisms by which glucose and amino acid metabolism are coordinated between the liver and skeletal muscle. 
